Beta Bionics (NASDAQ:BBNX) Now Covered by Truist Financial

Truist Financial assumed coverage on shares of Beta Bionics (NASDAQ:BBNX - Free Report) in a research report sent to investors on Monday morning, MarketBeat.com reports. The firm issued a buy rating and a $26.00 target price on the stock.

A number of other equities analysts have also recently commented on BBNX. The Goldman Sachs Group began coverage on Beta Bionics in a report on Friday, May 30th. They issued a "neutral" rating and a $16.00 target price for the company. Robert W. Baird began coverage on Beta Bionics in a report on Thursday, February 20th. They set a "neutral" rating and a $20.00 price objective for the company. Piper Sandler began coverage on Beta Bionics in a report on Monday, February 24th. They set an "overweight" rating and a $26.00 price objective for the company. Stifel Nicolaus began coverage on Beta Bionics in a report on Monday, February 24th. They set a "buy" rating and a $25.00 price objective for the company. Finally, Leerink Partnrs upgraded Beta Bionics to a "strong-buy" rating in a report on Monday, February 24th. Four analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $23.44.

Beta Bionics Stock Performance

Shares of Beta Bionics stock traded down $0.45 on Monday, reaching $17.78. The company had a trading volume of 317,195 shares, compared to its average volume of 530,150. The firm's 50-day simple moving average is $14.37. Beta Bionics has a 1 year low of $8.89 and a 1 year high of $24.50.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($0.52) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.01).

Insiders Place Their Bets

In other Beta Bionics news, CFO Stephen Feider sold 1,497 shares of the company's stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $17.89, for a total value of $26,781.33. Following the completion of the sale, the chief financial officer now directly owns 45,503 shares in the company, valued at approximately $814,048.67. This represents a 3.19% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last ninety days, insiders sold 4,519 shares of company stock worth $80,845.

Institutional Investors Weigh In On Beta Bionics

Several hedge funds have recently made changes to their positions in BBNX. Rhumbline Advisers purchased a new stake in shares of Beta Bionics in the 1st quarter worth $158,000. Evanson Asset Management LLC purchased a new stake in shares of Beta Bionics during the 1st quarter worth $475,000. Bank of New York Mellon Corp purchased a new stake in shares of Beta Bionics during the 1st quarter worth $316,000. Values First Advisors Inc. purchased a new stake in shares of Beta Bionics during the 1st quarter worth $457,000. Finally, Jennison Associates LLC purchased a new stake in shares of Beta Bionics during the 1st quarter worth $828,000.

Beta Bionics Company Profile

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.